Article Information
History
- January 31, 2024.
Article Versions
- Version 1 (July 31, 2023 - 20:54).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Lyndon P. James1,2,*,
- Fayette Klaassen3,
- Sedona Sweeney4,
- Jennifer Furin5,
- Molly F. Franke5,
- Reza Yaesoubi6,
- Dumitru Chesov7,8,
- Nelly Ciobanu9,
- Alexandru Codreanu9,
- Valeriu Crudu9,
- Ted Cohen10 and
- Nicolas A. Menzies2,3
- 1PhD Program in Health Policy, Harvard University, Cambridge, MA, USA
- 2Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- 3Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- 4Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
- 5Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
- 6Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
- 7Discipline of Pneumology and Allergology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova
- 8Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- 9Chiril Draganiuc Institute of Phthisiopneumology, Chisinau, Moldova
- 10Department of Epidemiology and Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
- ↵*Corresponding author: LPJ, Email: lyj519{at}mail.harvard.edu
Posted January 31, 2024.
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis
